Cytomed Therapeutics Limited Stock Market Value
| GDTC Stock | 2.96 0.47 13.70% |
| Symbol | CytoMed |
CytoMed Therapeutics Price To Book Ratio
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CytoMed Therapeutics. If investors know CytoMed will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CytoMed Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.22) | Revenue Per Share | Quarterly Revenue Growth (0.21) | Return On Assets | Return On Equity |
The market value of CytoMed Therapeutics is measured differently than its book value, which is the value of CytoMed that is recorded on the company's balance sheet. Investors also form their own opinion of CytoMed Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is CytoMed Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CytoMed Therapeutics' market value can be influenced by many factors that don't directly affect CytoMed Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CytoMed Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if CytoMed Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CytoMed Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
CytoMed Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to CytoMed Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of CytoMed Therapeutics.
| 12/08/2024 |
| 01/07/2025 |
If you would invest 0.00 in CytoMed Therapeutics on December 8, 2024 and sell it all today you would earn a total of 0.00 from holding CytoMed Therapeutics Limited or generate 0.0% return on investment in CytoMed Therapeutics over 30 days. CytoMed Therapeutics is related to or competes with OKYO Pharma, Candel Therapeutics, Anebulo Pharmaceuticals, Silo Pharma, Monopar Therapeutics, Senti Biosciences, and Processa Pharmaceuticals. CytoMed Therapeutics is entity of United States More
CytoMed Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure CytoMed Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess CytoMed Therapeutics Limited upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 5.44 | |||
| Information Ratio | 0.1639 | |||
| Maximum Drawdown | 46.75 | |||
| Value At Risk | (8.59) | |||
| Potential Upside | 11.48 |
CytoMed Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for CytoMed Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as CytoMed Therapeutics' standard deviation. In reality, there are many statistical measures that can use CytoMed Therapeutics historical prices to predict the future CytoMed Therapeutics' volatility.| Risk Adjusted Performance | 0.1446 | |||
| Jensen Alpha | 1.23 | |||
| Total Risk Alpha | 1.06 | |||
| Sortino Ratio | 0.2221 | |||
| Treynor Ratio | (4.35) |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of CytoMed Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
CytoMed Therapeutics Backtested Returns
CytoMed Therapeutics is very risky given 3 months investment horizon. CytoMed Therapeutics secures Sharpe Ratio (or Efficiency) of 0.15, which signifies that the company had a 0.15% return per unit of risk over the last 3 months. We were able to interpolate and analyze data for twenty-eight different technical indicators, which can help you to evaluate if expected returns of 1.11% are justified by taking the suggested risk. Use CytoMed Therapeutics Downside Deviation of 5.44, risk adjusted performance of 0.1446, and Mean Deviation of 5.18 to evaluate company specific risk that cannot be diversified away. CytoMed Therapeutics holds a performance score of 11 on a scale of zero to a hundred. The firm shows a Beta (market volatility) of -0.28, which signifies not very significant fluctuations relative to the market. As returns on the market increase, returns on owning CytoMed Therapeutics are expected to decrease at a much lower rate. During the bear market, CytoMed Therapeutics is likely to outperform the market. Use CytoMed Therapeutics expected short fall, day median price, and the relationship between the potential upside and accumulation distribution , to analyze future returns on CytoMed Therapeutics.
Auto-correlation | -0.83 |
Excellent reverse predictability
CytoMed Therapeutics Limited has excellent reverse predictability. Overlapping area represents the amount of predictability between CytoMed Therapeutics time series from 8th of December 2024 to 23rd of December 2024 and 23rd of December 2024 to 7th of January 2025. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of CytoMed Therapeutics price movement. The serial correlation of -0.83 indicates that around 83.0% of current CytoMed Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.83 | |
| Spearman Rank Test | -0.72 | |
| Residual Average | 0.0 | |
| Price Variance | 0.14 |
CytoMed Therapeutics lagged returns against current returns
Autocorrelation, which is CytoMed Therapeutics stock's lagged correlation, explains the relationship between observations of its time series of returns over different periods of time. The observations are said to be independent if autocorrelation is zero. Autocorrelation is calculated as a function of mean and variance and can have practical application in predicting CytoMed Therapeutics' stock expected returns. We can calculate the autocorrelation of CytoMed Therapeutics returns to help us make a trade decision. For example, suppose you find that CytoMed Therapeutics has exhibited high autocorrelation historically, and you observe that the stock is moving up for the past few days. In that case, you can expect the price movement to match the lagging time series.
Current and Lagged Values |
| Timeline |
CytoMed Therapeutics regressed lagged prices vs. current prices
Serial correlation can be approximated by using the Durbin-Watson (DW) test. The correlation can be either positive or negative. If CytoMed Therapeutics stock is displaying a positive serial correlation, investors will expect a positive pattern to continue. However, if CytoMed Therapeutics stock is observed to have a negative serial correlation, investors will generally project negative sentiment on having a locked-in long position in CytoMed Therapeutics stock over time.
Current vs Lagged Prices |
| Timeline |
CytoMed Therapeutics Lagged Returns
When evaluating CytoMed Therapeutics' market value, investors can use the concept of autocorrelation to see how much of an impact past prices of CytoMed Therapeutics stock have on its future price. CytoMed Therapeutics autocorrelation represents the degree of similarity between a given time horizon and a lagged version of the same horizon over the previous time interval. In other words, CytoMed Therapeutics autocorrelation shows the relationship between CytoMed Therapeutics stock current value and its past values and can show if there is a momentum factor associated with investing in CytoMed Therapeutics Limited.
Regressed Prices |
| Timeline |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| BTC | Bitcoin | |
| TRX | TRON | |
| BNB | Binance Coin |
Check out CytoMed Therapeutics Correlation, CytoMed Therapeutics Volatility and CytoMed Therapeutics Alpha and Beta module to complement your research on CytoMed Therapeutics. You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.
CytoMed Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.